OTC · Biotechnology

Avenue Therapeutics, Inc. (ATXI) Stock

$0.26 -32.94% OTC: ATXI Healthcare

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals.

Valuation

MetricValue
Price$0.26
Market Cap$856691
P/E Ratio-0.49
P/B Ratio0.71
P/S Ratio0.61
EPS (TTM)$-0.93
52-Week High$0.97
52-Week Low$0.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.83%
ROA-70.99%
ROCE-174.96%
Gross Margin-400.00%
Operating Margin-149.29%
Net Margin-124.79%
Debt/Equity0.00
Current Ratio1.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-4.0M$-8.0M$-15.0M$-11.0M$-3.0M
Net Profit$-4.0M$-4.0M$-10.0M$-12.0M$-3.0M
EPS$-3.29$-121.91$-73.48$-0.90$-0.93
Op Margin————-234.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.0M$7.0M$2.0M$3.0M$3.0M
Total Liabilities$1.0M$4.0M$1.0M$1.0M$1.0M
Cash$4.0M$7.0M$2.0M$3.0M$3.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-8.0M$-9.0M$-9.0M$-2.0M
Investing Cash Flow$0$0$-6.0M$0$0
Financing Cash Flow$-1.0M$-1.0M$0$8.0M$0
Net Cash Flow$1.0M$3.0M$-5.0M$1.0M$0
Free Cash Flow$-4.0M$-8.0M$-12.0M$-9.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.76
FCF Yield-126.65%
Quick Ratio1.90
Interest Coverage0.00
Return 1Y-35.02%
Return 3Y-99.70%
Return 5Y-99.99%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
ARDSAridis Pharmaceuticals, Inc. $0.00 — 0.00 $4457 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
MTVA $1.42 -1.39% -0.16 $3.13M 0.00%

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Avenue Therapeutics, Inc. is headquartered in US.

Avenue Therapeutics, Inc. (ATXI) stock trades at $0.26 with a market capitalization of $856691. The stock is valued at a price-to-earnings (P/E) ratio of -0.49, price-to-book of 0.71, price-to-sales of 0.61. Over the past 52 weeks the stock has ranged between $0.15 and $0.97, and currently trades 73.2% below its 52-week high.

On profitability, Avenue Therapeutics, Inc. generates a return on equity (ROE) of -65.83%, return on capital employed of -174.96%, an operating margin of -149.29%, a net profit margin of -124.79%.

Official website: www.avenuetx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides